New antibody AP601 enters human trials for Hard-to-Treat cancers

NCT ID NCT07165067

Recruiting now Disease control Sponsor: AP Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing a new drug called AP601 in 36 people with advanced solid tumors that have not responded to standard treatments. AP601 is a bispecific antibody designed to target a protein called CD73 found on some cancer cells. The main goal is to find the safest dose and check for side effects, not yet to prove it works against cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AP601 (a bispecific antibody)
What this could lead to: If successful, this could point toward a new treatment option for people with solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 36 participants, so it is primarily testing safety and dosing. It is too soon to know if AP601 will effectively shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOURS

Contacts and locations

Locations

Calvary Mater Newcastle
NOT_YET_RECRUITING

Waratah, New South Wales, 2298, Australia
Epworth HealthCare
RECRUITING

Melbourne, Victoria, 3121, Australia
Pindara Private Hospital
NOT_YET_RECRUITING

Brisbane, Queensland, 4217, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.